Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes.

Rosenstock J, Shenouda SK, Bergenstal RM, Buse JB, Glass LC, Heilmann CR, Kwan AY, MacConell LA, Hoogwerf BJ.

Diabetes Care. 2012 May;35(5):955-8. doi: 10.2337/dc11-1434. Epub 2012 Mar 19.

2.

Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus.

Levin PA, Mersey JH, Zhou S, Bromberger LA.

Endocr Pract. 2012 Jan-Feb;18(1):17-25. doi: 10.4158/EP11097.OR.

PMID:
21742605
3.

Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting.

Pawaskar M, Li Q, Hoogwerf BJ, Reynolds MW, Faries D, Engelman W, Bruhn D, Bergenstal RM.

Diabetes Obes Metab. 2012 Jul;14(7):626-33. doi: 10.1111/j.1463-1326.2012.01581.x. Epub 2012 Mar 8.

PMID:
22321776
4.

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.

Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group.

Ann Intern Med. 2005 Oct 18;143(8):559-69.

PMID:
16230722
6.

Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.

Levin P, Wei W, Wang L, Pan C, Douglas D, Baser O.

Curr Med Res Opin. 2012 Mar;28(3):439-46. doi: 10.1185/03007995.2012.654850. Epub 2012 Jan 23.

PMID:
22216894
8.

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.

Bunck MC, Diamant M, Cornér A, Eliasson B, Malloy JL, Shaginian RM, Deng W, Kendall DM, Taskinen MR, Smith U, Yki-Järvinen H, Heine RJ.

Diabetes Care. 2009 May;32(5):762-8. doi: 10.2337/dc08-1797. Epub 2009 Feb 5.

9.

Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration.

Buse JB, Han J, Miller S, MacConell L, Pencek R, Wintle M.

Curr Med Res Opin. 2014 Jul;30(7):1209-18. doi: 10.1185/03007995.2014.896329. Epub 2014 Mar 18.

PMID:
24621255
10.
11.

Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States.

Pawaskar M, Li Q, Hoogwerf BJ, Reynolds MW, Lee LJ, Fonseca V.

Endocr Pract. 2012 Sep-Oct;18(5):700-11. doi: 10.4158/EP11367.OR.

PMID:
22982784
12.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

13.

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.

Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K.

Diabetes Care. 2007 Jun;30(6):1487-93. Epub 2007 Mar 12.

PMID:
17353504
14.

Metabolic outcomes of elderly patient populations initiating exenatide BID versus insulin glargine in an ambulatory care setting.

Pawaskar M, Li Q, Reynolds MW.

Curr Med Res Opin. 2012 Jun;28(6):991-7. doi: 10.1185/03007995.2012.686901. Epub 2012 May 9.

PMID:
22519390
15.

Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis.

Glass LC, Qu Y, Lenox S, Kim D, Gates JR, Brodows R, Trautmann M, Bergenstal RM.

Curr Med Res Opin. 2008 Mar;24(3):639-44. doi: 10.1185/030079908X260862. Epub 2008 Jan 23.

PMID:
18218179
16.

Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy.

Karagianni P, Polyzos SA, Kartali N, Zografou I, Sambanis C.

Adv Med Sci. 2013;58(1):38-43. doi: 10.2478/v10039-012-0078-7.

PMID:
23640946
17.

Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents.

Davis SN, Johns D, Maggs D, Xu H, Northrup JH, Brodows RG.

Diabetes Care. 2007 Nov;30(11):2767-72. Epub 2007 Jun 26.

PMID:
17595353
18.

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. doi: 10.1016/j.clinthera.2008.08.006. Erratum in: Clin Ther. 2008 Oct;30(10):1937.

PMID:
18803987
19.

Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.

Horton ES, Silberman C, Davis KL, Berria R.

Diabetes Care. 2010 Aug;33(8):1759-65. doi: 10.2337/dc09-2062. Epub 2010 May 11.

20.

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.

Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM.

Diabetes Obes Metab. 2006 Jul;8(4):436-47.

PMID:
16776751
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk